comparemela.com

Latest Breaking News On - Based regimen - Page 1 : comparemela.com

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

Data reinforce ViiV Healthcare's leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention ViiV Healthcare, the global specialist HIV company majority-owned

United statesUnited kingdomNorth carolinaCity ofUnited kingdom generalKimberly smithKathleen quinnDan smithJosh williamsJeff mclaughlinSonya ghobrialMick readeyTim foleyJames dodwellKostenloser wertpapierhandelMelinda stubbee

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable switch option for people living with HIV For media and investors only ViiV

United statesUnited kingdomNorth carolinaCity ofUnited kingdom generalKimberly smithKathleen quinnJeff mclaughlinMick readeyAudrey abernathyTim foleyJames dodwellKostenloser wertpapierhandelOlayemi osiyemiMelinda stubbeeNao research institute

vimarsana © 2020. All Rights Reserved.